Moderna announced Wednesday that it is teaming up with Blackstone for its influenza program.
Under the collaboration, Blackstone will provide “up to $750 million,” according to press releases, with Blackstone eligible for undisclosed commercial milestones and low single-digit royalties. It wasn’t immediately clear Wednesday morning how much of the funding would be available to Moderna right away. Shares of the biotech $MRNA are up 3% premarket.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.